Influenza has a high incidence and burden in children \[[@CIT0001]\]. In particular, influenza B is reported to cause a disproportionate number of influenza-related deaths in children \[[@CIT0005]\]. Routine vaccination of children against influenza is recommended in the United States \[[@CIT0006]\] and other countries. Quadrivalent influenza vaccines containing 2 influenza A strains and 2 influenza B strains are increasingly used in vaccination programs to replace trivalent vaccines.

Inactivated influenza vaccines (IIVs) are administered to adults and children from 3 years of age at a dose of 0.5 mL, containing 15 µg of hemagglutinin (HA) per virus strain. In children under 3 years of age, the United States-licensed standard-dose is 0.25 mL, containing 7.5 µg of HA per virus strain. Both the 15 µg and 7.5 µg doses are available for this age group in some countries, including Canada, Brazil, Mexico, Finland, and the United Kingdom. The 7.5 µg dose was introduced in the 1970s to reduce reactogenicity, including febrile convulsions, associated with the whole virus vaccines available at the time \[[@CIT0007]\]. However, young children mount a variable immune response to the 7.5 µg dose \[[@CIT0012]\]. Currently available split virus vaccines are better tolerated than whole virus vaccines \[[@CIT0010], [@CIT0015], [@CIT0016]\], questioning the practice of using the 7.5 µg dose with IIVs.

The inactivated quadrivalent influenza vaccine (IIV4) manufactured in Quebec, Canada by GSK Vaccines is licensed at a double-dose (15 µg per antigen) for children from 6 months of age in Canada and Mexico, but it is currently only licensed for children 3 years of age and older in the United States. The only IIV4 licensed for use in children 6--35 months of age in the United States is Sanofi Pasteur's Fluzone Quadrivalent in a standard-dose (7.5 µg per antigen). No other IIV is approved in the United States in this age group either because immunogenic noninferiority to Fluzone could not be demonstrated \[[@CIT0017], [@CIT0018]\] or because of excessive reactogenicity \[[@CIT0019], [@CIT0020]\].

If the double-dose vaccine could be administered in young children without adverse effects on tolerability, this age group may benefit from potentially improved immunogenicity. In this study, we describe a phase III study that compared the safety and immunogenicity of a double-dose IIV4 manufactured by GSK Vaccines with the United States-approved standard-dose IIV4 in children 6--35 months of age.

METHODS {#s1}
=======

This was a phase III, randomized, controlled, observer-blind, multicenter trial in children 6--35 months of age (ClinicalTrials.gov Identifier NCT02242643). The trial was approved by independent ethics committees or institutional review boards, conducted in accordance with the Declaration of Helsinki, the International Conference on Harmonisation Good Clinical Practice (ICH-GCP) guidelines, ICH Harmonised Tripartite guideline for pediatric populations, and US regulatory requirements. Parents or legally acceptable representatives provided written informed consent.

Participants, Vaccines, and Study Design {#s2}
----------------------------------------

Children in stable health were recruited in the United States and Mexico during the 2014--15 influenza season (Supplementary Appendix). The double-dose IIV4 (GSK Vaccines, Quebec, Canada) contained 15 μg HA of each of the 4 strains: A/California/7/2009 (A/H1N1), A/Texas/50/2012 (A/H3N2), B/Brisbane/60/2008 (B/Victoria), and B/Massachusetts/2/2012 (B/Yamagata). The standard-dose IIV4 (Fluzone Quadrivalent; Sanofi Pasteur, Swiftwater, PA) contained 7.5 μg of HA of each of the same strains.

Children were randomized 1:1 to double-dose or standard-dose IIV4. Allocation to a study group at the investigator site was performed using an internet-based randomization system (SBIR). The randomization algorithm used a minimization procedure to balance the composition of treatment groups, accounting for age (6--17 and 18--35 months), center, and influenza vaccine priming status. The study aimed to enroll 40%--50% of children in the 6--17 months age group. Children were considered vaccine-primed if they had received 2 or more doses of influenza vaccine since July 1, 2010 or at least 1 dose of the 2013--14 influenza vaccine. Vaccine-primed children received a single dose on day 0. Vaccine-unprimed children received 1 dose on day 0 and another on day 28.

Study Endpoints {#s3}
---------------

Blood for serologic testing was obtained on days 0 and 28 from primed children and on days 0 and 56 from unprimed children. The following parameters were derived from hemagglutination inhibition (HI) titers: (1) geometric mean titer (GMT), (2) seroconversion rate (SCR), (3) seroprotection rate (SPR), and (4) mean geometric increase (MGI). Seroconversion rate was defined as the percentage of participants with either (1) prevaccination reciprocal HI titer \<1:10 and a postvaccination reciprocal titer ≥1:40 or (2) prevaccination reciprocal titer ≥1:10 and at least a 4-fold increase in postvaccination reciprocal titer. Seroprotection rate was defined as the percentage of participants who attained reciprocal HI titers of ≥1:40. Mean geometric increase was defined as the geometric mean of the within-subject ratios of the postvaccination/prevaccination reciprocal HI titer.

Parents recorded solicited injection site and general symptoms on the day of vaccination and for the next 6 days. Spontaneously reported symptoms were recorded until 28 days after vaccination. Serious adverse events (SAEs), potential immune-mediated diseases, and medically attended adverse events were recorded until the final study contact on day 180. Monitoring for febrile seizures was carried out throughout the study.

Study Objectives {#s4}
----------------

The primary objective was to demonstrate immunogenic noninferiority of the double-dose versus the standard-dose IIV4 28 days after completion of the vaccination course. Noninferiority criteria were met if, for each of the 4 vaccine strains, the upper limit of the 95% confidence interval (CI) of the GMT ratio (standard-dose/double-dose) was ≤1.5 and the upper limit of the 95% CI of the difference in SCR (standard-dose minus double-dose) was ≤10%.

If the primary objective was achieved, the secondary objective was to evaluate whether double-dose IIV4 produced an immune response against each of the vaccine strains that met Center for Biologics Evaluation and Research (CBER) criteria, ie, the lower limit of the 95% CI of the SCR was ≥ 40% and the lower limit of the 95% CI of the SPR was ≥ c\>70%. Additional secondary objectives were to (1) evaluate GMT, SPR, SCR, and MGI at 28 days after completion of the vaccination course, (2) describe the safety and reactogenicity of the vaccines, and (3) evaluate the relative risk of fever with double-dose versus standard-dose during the 2-day postvaccination period.

A post hoc evaluation was conducted to compare the immune response of the double-dose versus the standard-dose using CBER criteria conventionally applied to establish vaccine lot-to-lot consistency. Immunogenic superiority of the double-dose was concluded if the lower limit of the 95% CI of the GMT ratio (double-dose/standard-dose) was \>1.5 and the lower limit of the 95% CI of the difference in SCR (double-dose minus standard-dose) was \>10%.

Statistics {#s5}
----------

Enrollment of 1200 children per group (1020 evaluable subjects assuming an attrition rate of 15%) was planned to allow a global statistical power of 99% for the primary objective evaluation. The immunogenicity analysis was based on the per-protocol cohort and the safety analysis was based on the intent-to-treat cohort (Supplementary Appendix). Subgroup analyses according to age and priming status were conducted on the per-protocol cohort.

The overall type I error for the study was 5%. If the primary objective was met, the secondary objective of CBER criteria evaluation was tested to provide supportive evidence of immunogenicity. Calculation of 95% CIs is described in the Supplementary Appendix. The group GMT ratio was computed using an analysis of covariance model on the log-transformed titers. Analyses of immunogenicity excluded participants with missing or nonevaluable measurements at the postvaccination time point. Study power was calculated using PASS 2005 (Supplementary Appendix).

RESULTS {#s6}
=======

A total of 2424 and 2041 children were included in the intent-to-treat cohort and per-protocol cohort, respectively ([Figure 1](#F1){ref-type="fig"}). Demographics were similar in both vaccine groups ([Table 1](#T1){ref-type="table"}). In the per-protocol cohort, 57.5% of children were vaccine-primed; mean age was 24.6 and 13.3 months for primed and unprimed children, respectively. Other demographic characteristics were similar in primed and unprimed children ([Table 1](#T1){ref-type="table"}).

![Participant disposition.](piw06801){#F1}

###### 

Participant Demographics (Per-Protocol Cohort)

                                                All Children (Regardless Of Priming Status, 6--35 Months)   Primed Children (6--35 Months)   Unprimed Children (6--35 Months)                             
  --------------------------------------------- ----------------------------------------------------------- -------------------------------- ---------------------------------- ------------ ------------ ------------
  Age at first vaccination, months, mean (SD)   19.7 (8.7)                                                  19.9 (8.9)                       24.5 (6.2)                         24.8 (6.1)   13.1 (7.2)   13.5 (7.9)
  Age 6--17 months, n (%)                       400 (39.5)                                                  401 (39.0)                       74 (12.6)                          69 (11.8)    326 (76.5)   332 (75.1)
  \<12 months, n (%)                            213 (21.0)                                                  226 (22.0)                       0                                  0            213 (50.0)   226 (51.1)
  Age 18--35 months, n (%)                      613 (60.5)                                                  627 (61.0)                       513 (87.4)                         517 (88.2)   100 (23.5)   110 (24.9)
  Female, n (%)                                 462 (45.6)                                                  496 (48.2)                       264 (45.0)                         283 (48.3)   198 (46.5)   213 (48.2)
  Geographic ancestry, n (%)                                                                                                                                                                              
   Caucasian/European                           647 (63.9)                                                  667 (64.9)                       393 (67.0)                         400 (68.3)   254 (59.6)   267 (60.4)
   African/African American                     143 (14.1)                                                  140 (13.6)                       89 (15.2)                          78 (13.3)    54 (12.7)    62 (14.0)
   American Indian or Alaskan Native            23 (2.3)                                                    18 (1.8)                         15 (2.6)                           13 (2.2)     8 (1.9)      5 (1.1)
   South East Asian                             17 (1.7)                                                    20 (1.9)                         11 (1.9)                           14 (2.4)     6 (1.4)      6 (1.4)
   Other                                        183 (18.1)                                                  183 (17.8)                       79 (13.5)                          81 (13.8)    104 (24.4)   102 (23.1)

Abbreviatioins: IIV4, inactivated quadrivalent influenza vaccine; N, number of participants included in analysis; n, number of participants in stated category; SD, standard deviation.

Immunogenicity {#s7}
--------------

Both vaccines were immunogenic against all vaccine strains in terms of GMT values ([Figure 2](#F2){ref-type="fig"}). Immunogenic noninferiority of the double-dose IIV4 versus the standard-dose IIV4 was demonstrated for all vaccine strains ([Figure 3](#F3){ref-type="fig"}). Seroconversion rate, SPR, and MGI values were higher in the double-dose group compared with the standard-dose group in the whole study population (6--35 months of age, regardless of priming status; [Table 2](#T2){ref-type="table"}). The lower limit of the 95% CI for SCR was ≥40% for the double-dose IIV4 against all vaccine strains ([Table 2](#T2){ref-type="table"}), meeting CBER criteria for demonstration of adequate immunogenicity. For SPR, the lower limit of the 95% CI was ≥70% for all strains except B/Victoria ([Table 2](#T2){ref-type="table"}).

![Geometric mean titer for all vaccine strains in all children 6--35 months of age regardless of priming status and in each subgroup prevaccination and 28 days after completion of vaccination series (per-protocol cohort). CI, confidence interval; IIV4, inactivated quadrivalent influenza vaccine.](piw06802){#F2}

![Noninferiority of the double-dose versus the standard-dose in all children 6--35 months of age regardless of priming status: geometric mean titer (GMT) ratio and difference in seroconversion rate (SCR) at 28 days after completion of vaccination series (per-protocol cohort). CI, confidence interval; IIV4, inactivated quadrivalent influenza vaccine.](piw06803){#F3}

###### 

Immunogenicity Against Each Vaccine Strain at 28 Days After Completion of Vaccination Series in All Children 6--35 Months of Age Regardless of Priming Status (Per-Protocol Cohort)

                        A/H1N1   A/H3N2               B/Yamagata   B/Victoria                                                
  --------------------- -------- -------------------- ------------ -------------------- ------ ---------------------- ------ -------------------
  GMT, 1/DIL (95% CI)                                                                                                        
   Double-dose          1013     98.8 (90.3--108.2)   1013         97.7 (90.3--105.7)   1013   257.5 (240.9--275.3)   1013   55.1 (50.8--59.8)
   Standard-dose        1028     84.4 (76.9--92.6)    1028         84.3 (77.6--91.6)    1028   164.2 (151.8--177.6)   1028   33.4 (30.6--36.4)
  SCR, % (95% CI)                                                                                                            
   Double-dose          972      73.7 (70.8--76.4)    972          76.1 (73.3--78.8)    974    85.5 (83.2--87.7)      973    64.9 (61.8--67.9)
   Standard-dose        980      67.3 (64.3--70.3)    980          69.4 (66.4--72.3)    980    73.8 (70.9--76.5)      980    48.5 (45.3--51.6)
  SPR, % (95% CI)                                                                                                            
   Double-dose          1013     80.4 (77.8--82.8)    1013         82.2 (79.7--84.5)    1013   97.0 (95.8--98.0)      1013   66.0 (63.0--69.0)
   Standard-dose        1028     75.4 (72.6--78.0)    1028         77.8 (75.2--80.3)    1028   88.6 (86.5--90.5)      1028   49.8 (46.7--52.9)
  MGI (95% CI)                                                                                                               
   Double-dose          972      9.0 (8.4--9.7)       972          10.7 (10.0--11.6)    974    12.7 (11.7--13.7)      973    8.7 (8.1--9.4)
   Standard-dose        980      7.7 (7.1--8.3)       980          8.9 (8.2--9.7)       980    8.1 (7.5--8.8)         980    5.4 (5.0--5.8)

Abbreviations: CI, confidence interval; DIL, dilution; GMT, geometric mean titer; MGI, mean geometric increase; N, number of participants included in analysis; SCR, seroconversion rate; SPR, seroprotection rate.

Immunogenicity was higher in the double-dose group compared with the standard-dose group, particularly against vaccine B strains in children 6--17 months of age and unprimed children ([Table 3](#T3){ref-type="table"}; [Figure 2](#F2){ref-type="fig"}). When the unprimed group was further evaluated by age, it could be seen that the main difference between vaccines occurred in children 6--17 months of age. These observations prompted us to perform the post hoc evaluation comparing the immune response elicited by the vaccines in the whole study population and according to age group and priming status. The analysis indicated superior immunogenicity of the double-dose IIV4 against both vaccine B strains in children 6--17 months of age and all unprimed children. In children 6--17 months of age, the GMT ratio was 1.89 (95% CI, 1.64--2.17) for B/Yamagata and 2.13 (95% CI, 1.82--2.50) for B/Victoria ([Figure 4](#F4){ref-type="fig"} and Supplementary Table 1). Corresponding values in all unprimed children were 1.85 (95% CI, 1.59--2.13) and 2.04 (95% CI, 1.79--2.33). Superior immunogenicity of the double-dose was also observed for the same groups in terms of SCR difference ([Figure 4](#F4){ref-type="fig"} and Supplementary Table 1).

###### 

Comparison of Immunogenicity of the Double-Dose Versus the Standard-Dose According to Age and Priming Status at 28 Days After Completion of Vaccination Series (Per-Protocol Cohort)

                                                 A/H1N1   A/H3N2                 B/Yamagata   B/Victoria                                                
  ---------------------------------------------- -------- ---------------------- ------------ ---------------------- ----- ---------------------- ----- ---------------------
  6--17 months (regardless of priming status)                                                                                                           
  GMT, 1/DIL (95% CI)                                                                                                                                   
   Double-dose                                   400      42.7 (37.1--49.0)      400          58.9 (52.2--66.4)      400   151.0 (137.4--165.9)   400   68.7 (61.8--76.3)
   Standard-dose                                 401      43.2 (37.3--50.0)      401          54.8 (47.9--62.7)      401   79.1 (70.9--88.1)      401   31.9 (28.4--35.7)
  SPR, % (95% CI)                                                                                                                                       
   Double dose                                   400      61.3 (56.3--66.1)      400          70.3 (65.5--74.7)      400   94.3 (91.5--96.3)      400   78.3 (73.9--82.2)
   Standard-dose                                 401      59.9 (54.9--64.7)      401          67.8 (63.0--72.4)      401   77.6 (73.2--81.5)      401   51.4 (46.4--56.4)
  SCR, % (95% CI)                                                                                                                                       
   Double-dose                                   376      58.5 (53.3--63.5)      376          69.1 (64.2--73.8)      376   79.5 (75.1--83.5)      376   77.4 (72.8--81.5)
   Standard-dose                                 375      57.6 (52.4--62.7)      375          66.7 (61.6--71.4)      375   61.9 (56.7--66.8)      375   50.4 (45.2--55.6)
  MGI (95% CI)                                                                                                                                          
   Double-dose                                   376      6.0 (5.3--6.8)         376          10.2 (9.0--11.6)       376   12.3 (10.7--14.3)      376   12.3 (11.0--13.8)
   Standard-dose                                 375      6.1 (5.2--7.1)         375          8.8 (7.7--10.2)        375   6.1 (5.3--7.0)         375   5.7 (5.1--6.4)
  18--35 months (regardless of priming status)                                                                                                          
  GMT, 1/DIL (95% CI)                                                                                                                                   
   Double-dose                                   613      170.9 (155.2--188.3)   613          136.0 (123.7--149.6)   613   364.8 (336.7--395.3)   613   47.8 (42.6--53.6)
   Standard-dose                                 627      129.6 (116.3--144.3)   627          111.1 (100.6--122.7)   627   262.1 (239.3--287.1)   627   34.4 (30.4--38.8)
  SPR, % (95% CI)                                                                                                                                       
   Double-dose                                   613      92.8 (90.5--94.7)      613          90.0 (87.4--92.3)      613   98.9 (97.7--99.5)      613   58.1 (54.1--62.0)
   Standard-dose                                 627      85.3 (82.3--88.0)      627          84.2 (81.1--87.0)      627   95.7 (93.8--97.1)      627   48.8 (44.8--52.8)
  SCR, % (95% CI)                                                                                                                                       
   Double-dose                                   596      83.2 (80.0--86.1)      596          80.5 (77.1--83.6)      598   89.3 (86.5--91.7)      597   57.0 (52.9--61.0)
   Standard-dose                                 605      73.4 (69.7--76.9)      605          71.1 (67.3--74.7)      605   81.2 (77.8--84.2)      605   47.3 (43.2--51.3)
  MGI (95% CI)                                                                                                                                          
   Double-dose                                   596      11.7 (10.7--12.8)      596          11.1 (10.1--12.1)      598   12.9 (11.8--14.0)      597   7.0 (6.4--7.7)
   Standard-dose                                 605      8.9 (8.1--9.8)         605          9.0 (8.2--9.9)         605   9.7 (8.9--10.6)        605   5.2 (4.7--5.7)
  Primed (regardless of age)                                                                                                                            
  GMT, 1/DIL (95% CI)                                                                                                                                   
   Double-dose                                   587      158.8 (143.3--176.0)   587          118.4 (107.5--130.3)   587   334.3 (306.4--364.7)   587   38.1 (34.0--42.8)
   Standard-dose                                 586      115.0 (102.6--128.9)   586          90.4 (81.8--100.0)     586   242.2 (219.1--267.7)   586   26.7 (23.6--30.3)
  SPR, % (95% CI)                                                                                                                                       
   Double-dose                                   587      90.6 (88.0--92.9)      587          87.2 (84.2--89.8)      587   98.1 (96.7--99.1)      587   49.4 (45.3--53.5)
   Standard-dose                                 586      82.1 (78.7--85.1)      586          80.2 (76.7--83.4)      586   93.7 (91.4--95.5)      586   40.1 (36.1--44.2)
  SCR, % (95% CI)                                                                                                                                       
   Double-dose                                   570      80.5 (77.0--83.7)      570          77.9 (74.3--81.2)      572   86.5 (83.5--89.2)      571   48.0 (43.8--52.2)
   Standard-dose                                 563      70.3 (66.4--74.1)      563          67.1 (63.1--71.0)      563   78.0 (74.3--81.3)      563   38.4 (34.3--42.5)
  MGI (95% CI)                                                                                                                                          
   Double-dose                                   570      10.9 (10.0--12.0)      570          10.0 (9.1--10.9)       572   10.7 (9.9--11.6)       571   5.6 (5.1--6.1)
   Standard-dose                                 563      8.5 (7.7--9.3)         563          7.6 (6.9--8.3)         563   8.2 (7.6--8.9)         563   4.0 (3.6--4.4)
  Unprimed (regardless of age)                                                                                                                          
  GMT, 1/DIL (95% CI)                                                                                                                                   
   Double-dose                                   426      51.4 (44.7--59.1)      426          75.0 (66.0--85.3)      426   179.8 (163.7--197.4)   426   91.7 (83.8--100.3)
   Standard-dose                                 442      56.0 (48.4--64.8)      442          76.8 (66.9--88.3)      442   98.1 (88.1--109.3)     442   44.8 (40.1--50.0)
  SPR, % (95% CI)                                                                                                                                       
   Double-dose                                   426      66.2 (61.5--70.7)      426          75.4 (71.0--79.4)      426   95.5 (93.1--97.3)      426   89.0 (85.6--91.8)
   Standard-dose                                 442      66.5 (61.9--70.9)      442          74.7 (70.3--78.7)      442   81.9 (78.0--85.4)      442   62.7 (58.0--67.2)
  SCR, % (95% CI)                                                                                                                                       
   Double-dose                                   402      63.9 (59.0--68.6)      402          73.6 (69.0--77.9)      402   84.1 (80.1--87.5)      402   88.8 (85.3--91.7)
   Standard-dose                                 417      63.3 (58.5--67.9)      417          72.4 (67.9--76.7)      417   68.1 (63.4--72.6)      417   62.1 (57.3--66.8)
  MGI (95% CI)                                                                                                                                          
   Double-dose                                   402      6.9 (6.1--7.8)         402          11.8 (10.4--13.4)      402   16.0 (13.9--18.5)      402   16.2 (14.8--17.8)
   Standard-dose                                 417      6.8 (5.9--7.8)         417          11.2 (9.7--12.9)       417   8.0 (6.9--9.3)         417   8.0 (7.2--8.8)
  Unprimed (6--17 months)                                                                                                                               
  GMT, 1/DIL (95% CI)                                                                                                                                   
   Double-dose                                   326      36.2 (31.3--41.9)      326          56.7 (49.7--64.8)      326   146.8 (132.5--162.7)   326   84.6 (76.7--93.3)
   Standard-dose                                 332      38.0 (32.5--44.4)      332          54.1 (46.6--62.7)      332   71.1 (63.6--79.4)      332   35.5 (31.5--40.0)
  SPR, % (95% CI)                                                                                                                                       
   Double-dose                                   326      57.4 (51.8--62.8)      326          68.7 (63.4--73.7)      326   94.2 (91.0--96.5)      326   87.4 (83.3--90.8)
   Standard-dose                                 332      57.2 (51.7--62.6)      332          68.4 (63.1--73.3)      332   75.9 (70.9--80.4)      332   55.1 (49.6--60.6)
  SCR, % (95% CI)                                                                                                                                       
   Double-dose                                   304      54.9 (49.2--60.6)      304          68.4 (62.9--73.6)      304   79.3 (74.3--83.7)      304   87.2 (82.9--90.7)
   Standard-dose                                 309      55.0 (49.3--60.7)      309          68.0 (62.4--73.1)      309   58.9 (53.2--64.4)      309   54.4 (48.6--60.0)
  MGI (95% CI)                                                                                                                                          
   Double-dose                                   304      5.5 (4.7--6.3)         304          10.3 (8.9--11.9)       304   12.8 (10.7--15.1)      304   15.7 (14.0--17.6)
   Standard-dose                                 309      5.5 (4.6--6.5)         309          9.1 (7.7--10.6)        309   5.6 (4.7--6.6)         309   6.5 (5.8--7.3)
  Unprimed (18--35 months)                                                                                                                              
  GMT, 1/DIL (95% CI)                                                                                                                                   
   Double-dose                                   100      161.7 (125.9--207.7)   100          187.0 (143.6--243.6)   100   347.7 (296.3--407.9)   100   119.2 (96.8--146.7)
   Standard-dose                                 110      180.9 (141.0--232.1)   110          222.0 (173.3--284.4)   110   260.0 (217.5--310.8)   110   90.5 (73.2--111.8)
  SPR, % (95% CI)                                                                                                                                       
   Double-dose                                   100      95.0 (88.7--98.4)      100          97.0 (91.5--99.4)      100   100 (96.4--100)        100   94.0 (87.4--97.8)
   Standard-dose                                 110      94.5 (88.5--98.0)      110          93.6 (87.3--97.4)      110   100 (96.7--100)        110   85.5 (77.5--91.5)
  SCR, % (95% CI)                                                                                                                                       
   Double-dose                                   98       91.8 (84.5--96.4)      98           89.8 (82.0--95.0)      98    99.0 (94.4--100)       98    93.9 (87.1--97.7)
   Standard-dose                                 108      87.0 (79.2--92.7)      108          85.2 (77.1--91.3)      108   94.4 (88.3--97.9)      108   84.3 (76.0--90.6)
  MGI (95% CI)                                                                                                                                          
   Double-dose                                   98       13.9 (11.6--16.8)      98           18.0 (14.1--23.1)      98    32.5 (26.3--40.1)      98    18.0 (15.3--21.2)
   Standard-dose                                 108      12.4 (10.2--15.1)      108          20.7 (15.6--27.4)      108   22.8 (18.4--28.3)      108   14.2 (11.9--16.8)

Abbreviations: CI, confidence interval; DIL, dilution; GMT, geometric mean titer; MGI, mean geometric increase; N, number of participants included in analysis; SCR, seroconversion rate; SPR, seroprotection rate.

![Comparison of immunogenicity of the double-dose versus the standard-dose in all children 6--35 months of age regardless of priming status and in each subgroup: geometric mean titer (GMT) ratio and difference in seroconversion rate (SCR) at 28 days after completion of vaccination series (per-protocol cohort). CI, confidence interval; IIV4, inactivated quadrivalent influenza vaccine.](piw06804){#F4}

Safety and Reactogenicity {#s8}
-------------------------

Pain was the most common solicited injection site symptom, occurring in approximately 40% of children in both vaccine groups; severe (grade 3) pain occurred in 2.9% (95% CI, 2.0--4.1) and 1.7% (95% CI, 1.0--2.6) of children with the double-dose and standard-dose, respectively ([Table 4](#T4){ref-type="table"}). Fever (38.0°C) was reported in approximately 8% of children up to 7 days postvaccination; fever \>39.0°C occurred in approximately 2% of children ([Table 4](#T4){ref-type="table"}). During the 2-day postvaccination period (days 0--1), the incidence of fever (≥38.0°C) was similar in both groups ([Table 4](#T4){ref-type="table"}), and the relative risk (double-dose/standard-dose) was 0.97 (95% CI, 0.62--1.52; *P* = .9777). Twenty-two SAEs occurred in the double-dose group and 21 in the standard-dose group ([Table 4](#T4){ref-type="table"}), none considered related to vaccination. Febrile seizure was reported in 5 children in the double-dose group and in 4 children in the standard-dose group ([Table 4](#T4){ref-type="table"}).

###### 

Safety Outcomes Reported Throughout the Study (Intent-to-Treat Cohort)

                                                                                       Double-Dose IIV4 N = 1207^a^   Standard-Dose IIV4 N = 1217^a^          
  ------------------------------------------------------------------------------------ ------------------------------ -------------------------------- ------ -------------------
  Solicited^b^ injection site symptoms during 7-day postvaccination period                                                                                    
  Pain                                                                                 509                            44.0 (41.1--46.9)                462    40.1 (37.3--43.0)
   Grade 3^c^                                                                          34                             2.9 (2.0--4.1)                   19     1.7 (1.0--2.6)
  Redness                                                                              16                             1.4 (0.8--2.2)                   16     1.4 (0.8--2.2)
   Grade 3^c^                                                                          0                              \-                               0      \-
  Swelling                                                                             11                             1.0 (0.5--1.7)                   5      0.4 (0.1--1.0)
   Grade 3^c^                                                                          0                              \-                               0      \-
  Solicited general symptoms during 7-day postvaccination period                                                                                              
  Drowsiness                                                                           471                            40.6 (37.8--43.5)                471    40.9 (38.0--43.8)
   Grade 3^c^                                                                          36                             3.1 (2.2--4.3)                   34     3.0 (2.1--4.1)
  Fever (≥38.0°C)                                                                      91                             7.9 (6.4--9.6)                   86     7.5 (6.0--9.1)
   \>39.0°C                                                                            25                             2.2 (1.4--3.2)                   17     1.5 (0.9--2.4)
  Irritability/fussiness                                                               630                            54.4 (51.4--57.3)                582    50.5 (47.6--53.4)
   Grade 3^c^                                                                          61                             5.3 (4.0--6.7)                   45     3.9 (2.9--5.2)
  Loss of appetite                                                                     391                            33.7 (31.0--36.5)                385    33.4 (30.7--36.2)
   Grade 3^c^                                                                          26                             2.2 (1.5--3.3)                   19     1.6 (1.0--2.6)
  Unsolicited (spontaneously reported) symptoms during 28-day postvaccination period                                                                          
  All                                                                                  549                            45.5 (42.6--48.3)                537    44.1 (41.3--47.0)
   Grade 3^c^                                                                          70                             5.8 (4.5--7.3)                   75     6.2 (4.9--7.7)
   Related to vaccine                                                                  71                             5.9 (4.6--7.4)                   71     5.8 (4.6--7.3)
  Fever reported during 2-day postvaccination period                                                                                                          
  All (≥38.0°C)                                                                        42                             3.6 (2.6--4.9)                   43     3.7 (2.7--5.0)
  Febrile seizure^d^ during entire study period                                                                                                               
  All                                                                                  5                              0.4 (0.1--1.0)                   4      0.3 (0.1--0.8)
  Medically attended event^e^ during entire study period                                                                                                      
  All                                                                                  727                            60.2 (57.4--63.0)                719    59.1 (56.3--61.9)
  Potential immune-mediated disease during entire study period^f^                                                                                             
  All                                                                                  1^g^                           0.1 (0.0--0.5)                   1^g^   0.1 (0.0--0.5)
  Serious adverse event during entire study period^h^                                                                                                         
  All                                                                                  22                             1.8 (1.1--2.7)                   21     1.7 (1.1--2.6)

Abbreviations: CI, confidence interval; IIV4, inactivated quadrivalent influenza vaccine; N, number of participants included in analysis.

^a^For solicited injection site and general symptoms, only children for whom diary cards were returned are included (injection site symptoms: N = 1156 for double-dose IIV4 and N = 1151 for standard-dose IIV4; general symptoms: N = 1159 for double-dose IIV4 and N = 1152 for standard-dose IIV4).

^b^All solicited injection-site symptoms were considered related to vaccination.

^c^Grade 3 events were defined as follows: pain: child cried when the limb was moved or the limb was spontaneously painful; redness and swelling: \>100 mm surface diameter; drowsiness and irritability/fussiness: prevented normal activity; loss of appetite: did not eat at all; spontaneously reported symptom: prevented normal activity.

^d^In the double-dose group, seizures occurred 5, 50, 88, 106, and 168 days after the first vaccine dose. In the standard-dose group, 1 seizure occurred 178 days after the first vaccine dose and the others 39, 74, and 80 days after the second vaccine dose. All children recovered, and none of the seizures was considered by the investigator to be related to vaccination.

^e^Hospitalization, emergency room visit, medical practitioner visit.

^f^Autoimmune diseases and other inflammatory and/or neurologic disorders that may or may not have an autoimmune etiology, according to a protocol-specified list or investigators' judgment.

^g^Kawasaki's disease in the double-dose group and erythema multiforme in the standard-dose group, neither related to vaccination.

^h^Serious adverse events were defined as any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongs hospitalization, or results in disability or incapacity.

There was a modest increase in reactogenicity with regard to general symptoms in children 6--17 months of age compared with those aged 18--35 months with both the double-dose and standard-dose vaccines. With the double-dose vaccine, the fold-difference between the younger and older age groups ranged from 1.3 for loss of appetite to 2.7 for fever ≥38.0°C. With the standard-dose, the fold-difference ranged from 1.2 for loss of appetite to 1.6 for drowsiness and fever ≥38.0°C. The difference between age groups was unlikely to be due to chance because, in general, 95% CIs did not overlap. However, there were overlapping 95% CIs and thus no apparent age group differences with the standard-dose vaccine for fever ≥38.0°C and loss of appetite.

DISCUSSION {#s9}
==========

The introduction of IIV4 provides an opportunity to review long-accepted practices in administration of influenza vaccines. Since the 1970s, the standard-dose of IIVs in children less than 3 years of age has been 7.5 µg per antigen, half the dose given to older children and adults. The lower dose was intended to reduce reactogenicity and febrile convulsions observed with the whole virus vaccines that were in use at the time \[[@CIT0007]\]. However, young children mount a variable immune response to this lower dose, especially against vaccine B strains \[[@CIT0012]\]. In particular, vaccine-naive children less than 3 years of age mount a lower immune response compared with older or vaccine-primed children \[[@CIT0014], [@CIT0021]\]. The immune response in this vulnerable group could be improved by a change in practice to administer the double-dose, ie, same dose as used for children 3 years of age and above, and for adults. Increasing the immunogenicity of IIVs for young children is expected to improve their effectiveness, because the postvaccination HI antibody titer is inversely related to the risk of illness \[[@CIT0024], [@CIT0025]\]. However, there is controversy regarding the HI antibody titer necessary to offer high-level effectiveness \[[@CIT0024], [@CIT0025]\].

In the present study, both the double-dose and the standard-dose IIV4s were immunogenic against all vaccine strains in primed and unprimed children 6--35 months of age. The primary objective of the study---to fulfill US licensure criteria by demonstrating immunogenic noninferiority of the investigational IIV4 to a licensed IIV4 and acceptable safety of the investigational IIV4---was achieved. Most children receiving the double-dose IIV4 seroconverted (SCRs, 64.9%--85.5%), and most children achieved seroprotection (SPRs, 66.0%--97.0%). Similar immune responses have been achieved with the double-dose IIV4 in children of the same age in small studies conducted in 3 prior seasons \[[@CIT0026]\].

Greater antibody responses were observed with the double-dose IIV4 compared with the standard-dose, prompting us to perform a post hoc analysis to evaluate whether the double-dose elicited a superior immune response in terms of the CBER criteria usually applied to establish lot-to-lot consistency of influenza vaccines. In this analysis, the double-dose IIV4 did not reach superiority to the standard-dose in the overall population, the older age group (18--35 months), or previously primed children. However, in the younger age group (6--17 months) and in all unprimed children, the double-dose IIV4 met the applied superiority immune response criteria compared with the standard-dose against the B strains. It should be noted that the unprimed group was predominantly 6--17 months of age.

Several previous studies have compared the HI antibody response elicited by a double-dose versus a standard-dose IIV. The results of the present large phase III study contrast with those of a phase II study comparing GSK's double-dose IIV4 with the United States-approved standard-dose inactivated trivalent influenza vaccine (IIV3) (the corresponding IIV3 to the licensed IIV4 comparator used in the present study) \[[@CIT0026]\]. In the phase II study, the immune response with the double-dose and the standard-dose was similar against the strains common to both vaccines, but the sample size was too small to reliably detect differential immunogenicity against the vaccine B strains, especially in children 6--17 months of age \[[@CIT0026]\]. Two other small studies compared the immunogenicity of the United States-approved IIV3 administered as a standard or double-dose to young children in different years, with contrasting results \[[@CIT0021], [@CIT0029]\]. A 2008--09 trial found that a double-dose IIV3 elicited a higher immune response than a standard-dose in vaccine-unprimed children 6--23 months of age, reaching statistical significance in children 6--11 months of age for 2 of 3 vaccine strains \[[@CIT0021]\]. However, a 2010--12 trial found no difference in immunogenicity between standard-dose versus double-dose IIV3s in unprimed children \[[@CIT0029]\]. This prior experience highlights the necessity for trials of adequate size to reliably establish treatment benefit, and it suggests that observations made in 1 year may not be repeated in other years, because the baseline immunity of young children may vary. Furthermore, the dose effect on immunogenicity among IIVs may differ according to their manufacturing process \[[@CIT0023], [@CIT0026]\].

In the present study, the double-dose and standard-dose IIV4s had a similar reactogenicity profile despite the higher antigen content and volume of the double-dose. Injection site symptoms, including pain, occurred at a similar rate in both groups. There was no difference in the rate of fever over the 2-day postvaccination period between the 2 groups. Febrile seizures occurred at a similar rate in both groups, none were reported within 2 days of vaccination, and none were considered related to the vaccine. The finding that the higher antigen dose and volume in this study did not adversely affect tolerability in children confirms previous findings from studies comparing reactogenicity and safety of double-dose versus standard-dose IIVs \[[@CIT0021], [@CIT0026], [@CIT0029]\], and IIV4s versus IIV3s \[[@CIT0026], [@CIT0027], [@CIT0030]\].

CONCLUSIONS {#s10}
===========

In conclusion, a double-dose IIV4 may afford greater protection in young children against influenza B. Increased protection against influenza B, a potentially serious and life-threatening illness particularly in young children \[[@CIT0033]\], would be a beneficial clinical outcome. Use of the same vaccine dose for all eligible ages would also simplify the annual influenza vaccine campaign and reduce cost \[[@CIT0034]\] and logistic complexity. This study provides evidence to support a change in clinical practice to use a double-dose IIV4 (15 µg per antigen) in all children 6 months of age and older, once that dosing for a vaccine product has been approved.

Supplementary Data {#s11}
==================

Supplementary materials are available at *Journal of The Pediatric Infectious Diseases Society* online.
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Click here for additional data file.
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